NEW YORK (GenomeWeb News) – Massachusetts-based BG Medicine has acquired exclusive, worldwide rights from ACS Biomarker to develop and commercialize a clinical diagnostic test for acute atherothrombosis, the companies announced yesterday.
 
Scientists at the Cardiovascular Research Institute Maastricht in the Netherlands discovered the biomarker, which BG plans to develop into a test to diagnose transient blockages that cause stroke-like symptoms, coronary artery blockages, and other heart attack and stroke precursors.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.